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Conclusion: Carotid artery angioplasty and stenting can be success-
fully performed in patients with internal carotid artery pseudo-occlusion or
string sign.
Summary: This report focuses on carotid angioplasty and stenting in a
series of patients in whom the internal carotid artery (ICA) was thought
occluded by conventional ultrasound but who actually had string signs. The
authors treated 16 patients. Contrast computed tomography (CT) showed a
patent distal ICA in 14 of the 16 patients treated. Contrast-enhanced
ultrasound imaging also showed patent distal ICAs in 13 cases.
This is actually a series of very high-grade ICA stenosis and/or string
signs treated with angioplasty and stenting. The authors performed the
angioplasty and stent placement under cerebral protection. Duplex imaging
was performed at 14 days, 3 months, and every 6 months thereafter. CT
scans were obtained at 2 to 9 months, and the mean follow-up period was
9.9 months. Most patients had nonhemispheric symptoms as the indication
for treatment. Patients were treated with clopidogrel and aspirin before the
procedure and were maintained on clopidogrel 90 days after treatment and
on aspirin indefinitely. A 6F sheath was placed in the common carotid artery
and the ICA accessed with a 5F diagnostic vertebral catheter. A 0.035-inch
hydrophilic guide wire was then passed into the ICA, followed by the
catheter. An interceptor filter (Medtronic, Minneapolis, MN) was passed
through the catheter and opened in the lumen, and then the catheter was
withdrawn. Predilation was performed with a 3-mm balloon through the
filter wire, and then a self-expanding stent was placed in the proximal ICA and
dilated with a 5-mm balloon. If necessary, a second distal stent was placed.
Stent placement was successful in 13 of 16 patients. There were no
deaths, conversions, or cardiac complications. One patient had paresis in the
upper limb with recovery in 3 months. At follow-up, all 13 patients remained
with patent arterial lumens and were symptom free. After 2 to 9 months,
so-called string signs had calibers close or equal to those of normal arteries.
Comment: The title of this article is misleading. Although conven-
tional duplex ultrasound imaging showed the patients had occluded ICAs,
all in fact had patent distal ICAs either by contrast-enhanced ultrasound or
contrast CT scanning. The authors of the article, the Journal of Vascular and
Interventional Radiology reviewers, and the editors should be ashamed for
permitting such a misleading title. What the authors have shown us is that in
their institution, conventional duplex ultrasound imaging is likely below
standard in distinguishing high-grade carotid stenosis from occlusion. They
have shown us that CT angiography and contrast-enhanced ultrasound
imaging can detect carotid string signs, something we already knew. They
have also shown us that if you can get a wire across a high-grade stenosis,
then you can perform angioplasty and stenting, again something we already
knew. They have demonstrated that such procedures can be performed, but
whether they should be performed is an entirely different question.
A Large-Scale Study of the Upper Arm Basilic Transposition for
Hemodialysis
Glass C, Porter J, Singh M, et al. Ann Vasc Surg 2010;24:85-91.
Conclusion: Basilic vein transposition fistulas have excellent matura-
tion rates and good functional patency at 1 year. Major limitations to
long-term durability are the need for frequent revisions and central venous
stenosis.
Summary: The fistula-first initiative set a goal of 65% prevalence of
autogenous fistulas for hemodialysis access to be achieved in the United
States by 2009. Multiple studies in the recent past (10 during 2007-2009
alone) have examined maturation and patency rates of basilic vein transpo-
sition. The authors used basilic vein transposition as their third choice in the
construction of dialysis access, with radiocephalic the first choice and bra-
chiocephalic fistula the second choice. In this article they reviewed the results
of basilic vein transposition from April 2001 to June 2008. This retrospec-
tive study included information on demographics, volume flow creation,
maturation and patency rates, postoperative complications, and the need for
secondary interventions as well as overall mortality.
There were 217 upper arm basilic vein transposition fistulas in the
study. Fifty-three percent of the patients were men and there were 215
patients with a mean of 2.9 previous surgical access attempts before basilic
vein transposition. Only 14% of the time was basilic vein transposition the
initial fistula. Mean flow at time of fistula creation was 347 mL/min (range,
10-880 mL/min). The maturation rate was 87%. Mortality related to theprocedure was 0.5%. At 6, 12, and 24 months, primary patency rates were
63%, 40%, and 26%, and primary assisted patency rates were 74%, 56%, and
38%, respectively. Secondary patency rates at 6, 12, and 24 months were
85%, 72%, and 65%, respectively. The most common complication before
maturation was fistula thrombosis (16%), and the most frequent cause of
fistula failure was central venous stenosis (22%).
Comment: What makes this article stand out among the numerous
reports on basilic vein transposition have been published in the recent past is the
very high initial maturation rate. The authors attribute this to a technical
modification of the procedure. They noted previously that an area of the vein in
the upper part of the wound as it passes centrally was a frequent site of intimal
hyperplasia. They hypothesize this was caused by tethering of the vein by a large
profunda branch in the upper arm. The authors now routinely divide this branch
and all entering veins as high as they can reach in the axilla and postulate that the
smoother course of the transposition that this allows results in improved
maturation. The division of the profunda vein appears to cause no significant
complications, and therefore, it seems reasonable to incorporate this technical
modification of basilic vein transposition into the operation.
A Comparison of Clopidogrel Responsiveness in Patients With versus
Without Chronic Renal Failure
Park SH, Kim W, Park CS, et al. Am J Cardiol 2009;104:1292-5.
Conclusion: Patients with chronic renal failure have decreased respon-
siveness to clopidogrel compared with patients without chronic renal failure.
This decreased responsiveness is not corrected by an increase in the clopi-
dogrel dosage.
Summary: No antiplatelet effects are detectable in up to 30% of
patients receiving clopidogrel. It has been shown that chronic renal failure
(CRF) is a risk factor for stent thrombosis (J Am Coll Card 2007;50:501-8).
The present study was therefore performed to assess platelet responsiveness
to clopidogrel in patients with CRF. CRF was designated as a serum
creatinine3 mg/dL, and platelet responsiveness was expressed in terms of
P2Y12 reaction units (PRUs) and baseline PRUs in percentage of inhibition.
The effects of drugs that selectively act on the P2Y12 receptor can be
evaluated when adenosine diphosphate, a platelet receptor stimulator, is
mixed with prostaglandin E1. In these cases, the P2Y12 receptors activated
by adenosine diphosphate are inhibited by prostaglandin E1. Baseline PRU
values are measured using thrombin receptor-activating peptide. The per-
centage of platelet inhibition by clopidogrel is calculated by using the
baseline PRU value and the PRU value obtained after administration of
clopidogrel.
The study was performed in Korea and 94.4% of participants were men.
Patients with CRF for 6 months were randomized assigned to receive 75
mg of clopidogrel daily (group II, n  18) or 150 mg of clopidogrel daily
(group III, n 18). Group I was a control group with normal renal function
(n 23). Groups I and II received a once-daily dose of 75 mg of clopidogrel
for 4 weeks, and group III received a once-daily dose of 150 mg of
clopidogrel for 4 weeks. Primary efficacy variables among the groups were
the PRU value and the percentage of inhibition. There was a significant
difference in the PRU values among the three groups (232 86 in group I,
308  70 in group II, 302  81 in group III; P  .013) and in the
percentage of inhibition (35 20 in group I, 21 16 in group II, 23 14
in group III; P  .026). There were no significant differences in PRUs or
percent inhibition between groups II and III.
Comment: The study has several limitations that preclude its applica-
tion to all populations. Most specifically, almost all participants were men
and it was conducted in an exclusively Korean population. Nevertheless, it
highlights the potential adverse effect of renal failure on clopidogrel effec-
tiveness. Clinicians are left in a bit of a difficult situation in that it appears
renal failure makes clopidogrel less effective. In addition, this lack of effec-
tiveness cannot be overcome by doubling the dose. However, this study used
only one measure of platelet inhibition by clopidogrel. The drug may have
other effects that are beneficial in patients with renal failure that are not
measured by the methodology that was used.
Infectious Burden and Carotid Plaque Thickness: The Northern Man-
hattan Study
Elkind MSV, Luna JM, Moon YP, et al. Stroke 2010;41:e117-22.
Conclusion: Carotid plaque thickness in a multiethnic cohort is asso-
ciated with a quantitative weighted index of infectious burden derived from
the magnitude of association of individual infections with stroke.
797
